Abstract
This article reviews the natural history of HPV infection covering key aspects of cell biology, virology and immunology. The oncogenic HPV lifecycle is characterised by infection in basal cells of anogenital epithelia with virus production dependent on epithelial differentiation and virions produced only in terminally differentiated cells. Natural control of an oncogenic type HPV infection depends on appropriate activation of innate immune mechanisms leading to stimulation of adaptive immunity in the form of specific T cells against viral proteins such as E2, E6 and E7 which can effect clearance of the virally infected cells. Neutralising antibodies are detected in about 50% of women who have cleared such infections but are not necessarily protective against future infection by the same HPV type and are never therapeutic. In addition, the stealthy lifecycle of the virus which causes little or damage and no viraemia as well as various viral immune evasion strategies sometimes allows the virus to avoid immune detection providing for persistent infection which is the major risk factor for development of intraepithelial neoplasia. Oncogenic HPV infection is necessary but insufficient for development of a cervical cancer and additional genetic changes are acquired over time through selection including those that allow for immune escape from immune surveillance.
Keywords: Immune escape, interferon, T regulatory cells, cytotoxic T lymphocytes (CTL), antigen presenting cells (APC), neutralising antibodies, human leucocyte antigen (HLA)
Current Cancer Therapy Reviews
Title: From HPV Infection to Oncogenesis: A Brief Review of the Complex Immunobiological Events
Volume: 6 Issue: 2
Author(s): Peter L. Stern and Mark H. Einstein
Affiliation:
Keywords: Immune escape, interferon, T regulatory cells, cytotoxic T lymphocytes (CTL), antigen presenting cells (APC), neutralising antibodies, human leucocyte antigen (HLA)
Abstract: This article reviews the natural history of HPV infection covering key aspects of cell biology, virology and immunology. The oncogenic HPV lifecycle is characterised by infection in basal cells of anogenital epithelia with virus production dependent on epithelial differentiation and virions produced only in terminally differentiated cells. Natural control of an oncogenic type HPV infection depends on appropriate activation of innate immune mechanisms leading to stimulation of adaptive immunity in the form of specific T cells against viral proteins such as E2, E6 and E7 which can effect clearance of the virally infected cells. Neutralising antibodies are detected in about 50% of women who have cleared such infections but are not necessarily protective against future infection by the same HPV type and are never therapeutic. In addition, the stealthy lifecycle of the virus which causes little or damage and no viraemia as well as various viral immune evasion strategies sometimes allows the virus to avoid immune detection providing for persistent infection which is the major risk factor for development of intraepithelial neoplasia. Oncogenic HPV infection is necessary but insufficient for development of a cervical cancer and additional genetic changes are acquired over time through selection including those that allow for immune escape from immune surveillance.
Export Options
About this article
Cite this article as:
L. Stern Peter and H. Einstein Mark, From HPV Infection to Oncogenesis: A Brief Review of the Complex Immunobiological Events, Current Cancer Therapy Reviews 2010; 6 (2) . https://dx.doi.org/10.2174/157339410791202565
DOI https://dx.doi.org/10.2174/157339410791202565 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Plant and Animal Steroids a New Hope to Search for Antiviral Agents
Current Medicinal Chemistry Genomic Instability in Cancer: Molecular Mechanisms and Therapeutic Potentials
Current Pharmaceutical Design Hot Melt Extruded and Injection Moulded Dosage Forms: Recent Research and Patents
Recent Patents on Drug Delivery & Formulation Management of Endometrial Cancer: A Review
Reviews on Recent Clinical Trials Development of Ribonucleotide Reductase Inhibitors: A Review on Structure Activity Relationships
Mini-Reviews in Medicinal Chemistry Integrative Approaches for microRNA Target Prediction: Combining Sequence Information and the Paired mRNA and miRNA Expression Profiles
Current Bioinformatics Tumor Escape from Immune Response: Mechanisms and Targets of Activity
Current Drug Targets Recent Patents on Stimuli Responsive Hydrogel Drug Delivery System
Recent Patents on Drug Delivery & Formulation Applications of Nanosystems to Anticancer Drug Therapy (Part I. Nanogels, Nanospheres, Nanocapsules)
Recent Patents on Anti-Cancer Drug Discovery Sunitinib in the Treatment of Thyroid Cancer
Current Medicinal Chemistry Impact of RET Screening on the Management of Multiple Endocrine Neoplasia Type 2A: 10 Years Experience and Follow-Up in Three Families
Endocrine, Metabolic & Immune Disorders - Drug Targets Cucurbitacin IIb from Ibervillea sonorae Induces Apoptosis and Cell Cycle Arrest via STAT3 Inhibition
Anti-Cancer Agents in Medicinal Chemistry Working Towards the Development of Vaccines for the Treatment and Prevention of Early Breast Cancer
Current Cancer Therapy Reviews Pre-CKD- Do we Need Another Hero?
Current Vascular Pharmacology α(N)-Heterocyclic Thiosemicarbazones: Iron Chelators that are Promising for Revival of Gallium in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Image Fusion Based on Estimation Theory: Applied to PET/CT for Radiotherapy
Recent Patents on Medical Imaging A Review on Chemical Profile of Coumarins and their Therapeutic Role in the Treatment of Cancer
Current Drug Delivery Multiple VEGF Family Members are Simultaneously Expressed in Ovarian Cancer: a Proposed Model for Bevacizumab Resistance
Current Pharmaceutical Design A Comparative Evaluation of In Vitro Antioxidant, Antimicrobial and Cytotoxic Properties of Microwave and Soxhlet Assisted Extracts of Solanum viarum Fruits
The Natural Products Journal Highlights in Peptide Nanoparticle Carriers Intended to Oral Diseases
Current Topics in Medicinal Chemistry